The Patent Trial and Appeal Board Again Survives Supreme Court Review
For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.

For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.